Compare Bristol-Myers Squibb Co (BMY) vs Teucrium Corn Fund (CORN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Teucrium Corn Fund — how do they compare? Bristol-Myers Squibb Co trades at $58.52 (market cap $116.30B), while Teucrium Corn Fund trades at $17.67. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Teucrium Corn Fund pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals.
| BMY | CORN | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $62.37 | $19.12 |
52-Week Low | $42.60 | $16.46 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
CORN stock trades at $17.55 with a slight 0.4% daily gain, showing bullish technical momentum with strong moving average support. The company's financial ratios remain undisclosed in current data, limiting fundamental visibility. Recent partnership news with Hormel Foods for CORN NUTS brand licensing provides potential growth catalyst, while technical indicators suggest continued upward pressure with key resistance at $18.
Outlook remains cautiously optimistic given bullish technical signals and brand expansion opportunities, though limited financial transparency presents valuation challenges. Key risks include commodity price volatility and competitive pressures in the snack food sector. Investors should monitor upcoming earnings for fundamental clarity while technical momentum supports near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Teucrium Corn Fund
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →
